Vaccine: Agriflu
Company: Novartis
Approval Date: Oct. 24
Protects Against: Influenza

Novartis' ($NVS) Agriflu had a rough start to the 2012-2013 flu season. Switzerland, Canada, Italy and several other European countries banned the vaccine in October due to the discovery by the company of small clumps of virus particles in some batches. About 488,000 doses were affected by the ban. Novartis pulled the vaccine as drug regulators determined whether it was safe. The countries eventually lifted the ban and Novartis went on its merry way distributing the vaccine. The FDA approved Agriflu a bit later than many of the other flu vaccines, giving it the go-ahead Oct. 24.

For more:
Canada, Switzerland lift ban on Novartis flu vaccine
Canada joins in on Novartis vaccine suspension
Germany, France join crowd withdrawing Novartis vaccines
Under regulatory cloud, CEO says Novartis must boost quality


Suggested Articles

Merck just last month won the world's first licensure for an Ebola vaccine. Now, an international group authorized funding to establish a stockpile.

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.